Semaxanib sugen

IDrugs

Volumn 4, Issue 9, 2001, Pages 1061-1067

  Sakamoto, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746998393     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. 191353 SUGEN Inc ANNUAL REPORT 1394 December
2. 42683 SUGEN to initiate clinical trials with flk-1 TK angiogenesis inhibitors in 1997. SUGEN Inc PRESS RELEASE 1997 January 07
3. 64484 SUGEN Inc announces initiation of phase I angiogenesis inhibitor study. SUGEN Inc PRESS RELEASE 1997 September 30 • Use ofsemaxanib to treat solid tumors.
4. 72380 Angiogenesis in ischémie heart disease. Ware JA, Simon M NAT MED 19973 158 -164 • Provides the rationale for selective flk-1 tyrosine kinase inhibitors, and describes the role of VEGF growth factors on wound healing and arterial collateral development.
5. 79022 Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-setective inhibitor. Aiello LP, Bursell SE. Clermont A, Dun E, Ishii H, Takagi C. Mori F, Ciulta TA, Ways K, Jirousek M, Smith LE, King GL DIABETES 1997 46 9 1473 -1480
6. 83739 Effect of the Flk-1 antagonist SU5416 on tumor growth, angiogenesis and micro-hemodynamics. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Ullrich A, Hirth KP, Fong TA PROC AM ASSOC CANCER RES 1998 39 New Orleans Abs 651
7. 87300 SUGEN Inc. initiating phase l/ll clinical trial of SU5416 angiogenesis inhibitor in Kaposi's sarcoma. SUGEN Inc PRESS RELEASE 1998 May 15
8. 91967 Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibhors that exhibit selectivity toward particular receptor tyrosine kinases. Sun L, Tran N, Tang F, App H, Hirth P, McMahon G, Tang C J MED CHEM1998 41 14 2588 - 2603 • A new scaffold with broad kinase inhibitory activity is disclosed.
9. 93021 SUGEN and Taiho create strategic cancer alliance to develop angiogenesis inhibitors. SUGEN Inc PRESS RELEASE 1998 July 31
10. 94467 SUGEN awarded patent for angiogenesis inhibitor, SU5416, and related family of compounds. SUGEN Inc PRESS RELEASE 1998 August 12
11. 96876 SUGEN to initiate additional phase II trials with SU-101. SUGEN Inc PRESS RELEASE 1998 September 18
12. 04331 SUGEN announces interim phase I data from its angiogenesis inhibitor, SU-5416, at colon cancer conference. SUGEN Inc PRESS RELEASE 1998 November 09 Reported side effects of semaxanib.
13. 05306 DRUG DEV PIPELINE 1998 3 7 1 - 4
14. 10136 Tyrosine kinase inhibitors in cancer treatment (part II). Trader P EXPOP1NTHER PAT 1998 & 12 1599-1625 •• A complete review of the kinase inhibitor literature prior to 1997.
15. 21926 SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascular izat ion, and growth of multiple tumor types. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A CANCER RES 1999 59 1 99 -106
16. 25696 American Society of Clinical Oncology - 35th Annual Meeting (Part I), Atlanta, G A, USA. Boven E 1DDB MEETING REPORT 1999 May 15-18
17. 26004 American Society of Clinical Oncology - 35th Annual Meeting (Part III), Atlanta, GA, USA. McKinnon C IDDB MEETING REPORT 1999 May 15-18 • Phase l/ll study in patients with AIDS-related Kaposi's sarcoma.
18. 26969 Food and Drug Administration signs off on SUGEN's clinical strategy to move directly into phase III trials with SU-5416, lead angiogenesis inhibitor. SUGEN Inc PRESS RELEASE 1999 June 04 • Semaxanib in colorectal and lung cancer patients.
19. 30942 Angiogenesis in cancer, vascular, rheumatoid and other diseases. FdkmanJ AMTMED19951 127-31 • Effects of VEGFgmwth factors on tumor formation and rheumatoid arthritis.
20. 30947 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders [see comments]. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al NEW ENGL J MED 1994 331 1480 1487 • Discusses the SAR of substituted 3-indolin-2-ones and the effects of VEGF growth factors on retina.
21. 30951 Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. Brown LF, Harrist TJ, Yeo KT, Stahle Backdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M J INVEST DERMATOL 1995 104 5 744 - 749 • Provide the rationale for selective flk-1 tyroslne kinase inhibitors and discusses the effects of VEGF on psoriasis and other skin diseases.
22. 30958 Vascular endothelial growth factor (VEGF) and its receptors. Neufeld G, Cohen T, Gengrinovitch S, Portorak Z FASEB J1999 13 1 9 - 22
23. 30961 Rote of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Fong GH, Rossant J, Gertsenstein M, Breitman ML NATURE 1995 376 6535 66 - 70
24. 330968 Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M CELL 1998 92 6 735 - 745
25. 30973 Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'kinase/AM signal transduction pathway. Requirement for Flk-1/KDR activation. Gerber HP, McMurtrey A, Kowalski J, Van M, Keyt BA, Dixit V, Ferrara N J BIOL CHEM 1998 273 46 30336 - 30343
26. 30992 Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC M4TURE1995 376 6535 62 - 66 • Flk-1 receptor knockout mice phenotype.
27. 30996 Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A NATURE 1994367576-579
28. 30999 Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N J BIOL CHEM 1996 271 105638-5646 • Phosphorylation of flt-1 receptor.
29. 41382 Pharmacia & Upjohn's SUGEN Inc presents results of phase I trial of lead angiogenesis inhibitor, SU5416, in Kaposi's Sarcoma at ICAAC. SUGEN Inc PRESS RELEASE 1999 September 27
30. 62894 SU5416 and SU6668: Comparative differences in toxicrty profile in rats following intravenous administration. Chanda SM, Sukbunthemg J, Yang C, Kirn TW, Kirkpatrick JB, Krauser K, Antonian L, Shawver LK, Wagner GS PROCAMASSOC CANCER RES 2000 41 April 1-5 Abs 4470
31. 68486 American Society of Clinical Oncology 36th Annual Meeting (Part IX), New Orleans, LA, USA. Morse MA IDDB MEETING REPORT 2000 May 20-23 Phase I trials reporting toxicities ofsemaxanib.
32. 69783 Results of a phase 1 dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Stopeck A PROC AM SOC CLIN ONCOL 200019 May 20-23 Abs 802
33. 74505 Drug development pipeline. Pharmacia Corp COMPANY COMMUNICATION 2000 July 13
34. 375431 CPT 2000 (Part IV), Seventh Conference on Clinical Pharmacology and Therapeutics and Fourth Congress of the European Association for Clinical Pharmacology and Therapeutics, Florence, Italy. Archibald K IDDB MEETING REPORT2000 July 15-20 Semaxanib effects in nude mice with xenografts.
35. 376895 Anti-tumour activity of SU5416 in association with gemcHabine in vitro and in mice bearing MIA PaCa-2 human pancreas adenocarcinoma. Bocci G, Boggi U, Danes! R, Fioravanti A, Bonanomi G, Boschi E, Ferretti A, Luperi G, Pietrabissa A, Mosca F, del Tacca M BR J CLIN PHARMACOL 2000 July 15-20 Abs 953
36. 85699 Pharmacia presents new data on cancer drugs showing promise in controlling and shrinking tumors - molecular and hormonal options unveiled at international symposium. Pharmacia Corp PRESS RELEASE 2000 October 13 • Phase l/ll trial with semaxanib in patients with advanced stage cancer.
37. 91320 Dose finding study of cisplatin, gemcitabine and SU-5416 in patients with advanced malignancies. Giaccone G, Rosen L, Kuenen B, Ruijter R, van der Vijgh W, Peters G, Huisman H, Hoekman K, Scigalla P, Smrt E, Pinedo H NCI EORTC SYMP NEW DRUGS CANCER THER 2000 11 November 7-11 Abs 263 • Unacceptable toxicities in patients who receive semaxanib in combination with cisplatin/gemcitabine.
38. 91991 American Society of Hematology 42nd Annual Meeting OVERNIGHT REPORT (Part II) San Francisco, CA, USA. McKinnon C IDDB MEETING REPORT 2000 December 1-5
39. 93497 The tyrosine kinase inhibitor SU5416 reduces proliferation and colony-formation of primary AML blasts after co-culture with a newly derived endothelial feeder cell line. Redler W, Mende T, Tinnefeid H, Philippe S, Gehling U, Vohwinkel G, Scigalla P, Hossfeld D K BLOOD 2000 9611 SuppM Abs 525
40. 02241 Milestone reached in the study of Pharmacia's angiogenesis signaling inhibitor-researchers worldwide to evaluate Semaxanib (SU5416) in phase III trial to treat advanced colorectal cancer. Pharmacia Corp PRESS RELEASE200-\ March 16
41. 05309 Novel tyrosine kinase inhibitors block Kit activation and growth of samll cell lung cancer cells. Krystal G W, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Upson K PROC AM ASSOC CANCER RES 2001 42 Abs 4319
42. 09850 Phase l/ll study of SU5416 in combination with irinotecan/5FU/LV (IFL) in patients with metastatic colorectal cancer. Rothenberg ML, Berlin JD, Cropp GF, Fleischer AC, Schumaker RD, Hände KR, Culley A, Dorminy C, Donnelly E, Chen J, Schaaf L, Hannah AL PROC AM SOC CLIN ONCOL 2001 20 Pt 1 Abs 298
43. 09993 A phase l/ll trial and pharmacokinetic (PK) study of SU5416 in combination with paclitaxel/carboplatin. Rosen PJ, Kabbinavar F, Figlin RA, Parson M, Laxa B, Hernandez L, Mayers A, Cropp GF, Hannah AL, Rosen LS PROCAM SOC CLIN ONCOL 2001 20 Pt 1 Abs 389
44. 09995 A phase I and pharmacokinetic study of single oral administration of SU5416 in patients with advanced solid tumors. Salzberg M, Pless M, Rochiltz C, Herrmann R, Cropp G, Hannah A, Scigalla P PROC AM SOC CLIN ONCOL 2001 20 Pt 1 Abs 390
45. 09997 A phase I pharmacokinetic and pharmacodynamic study of SU5416 and doxorubicin (ADR) in inflammatory breast cancer (IBC). Overmoyer B, Robertson K, Persons M, Shenk R, Lewin J, Jesberger J, Ziats N, Tserng K, Hoppel C, Harman P, Cooper B ef al PROC AM SOC CLIN ONCOL 2001 20 Pt 1 Abs 391
46. 10535 SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Kindler HL, Vpgelzang NJ, Chien K, Stadier WM, Karczmar G, Heimann R, Vokes EE PROC AM SOC CLIN ONCOL 2001 201 Abs 1359
47. 10577 Phase II study of the anti-angiogenic Flk-1 tyrosine kinase inhibitor SU5416 in melanoma: Initial results, gajewki TF, Rickinger S, Heimann R, Karcztnar G, Rini B, Dragovich T PROC AM SOC CLIN ONCOL 2001 20 1 Abs 1436
48. 11014 A phase II study with SU-5416 in patients with C-Kit positive AML. Fielder H, Tinnefeid T, Wende U, Gehling G, Volwinkel S, Kelsey P, Scilgalia P, Hossfeld DK PROC AM SOC CLIN ONCOL 2001 20 1 Abs 1148
49. 11307 Biotransformation of the anti-angiogenic compound SU5416. Antonian L, Zhang H, Yang C, Wagner G, Shawver LK, Shel M, Ogilvie B, Madan A, Parkinson A DRUG METAB DISPOS 2000 28 12 1505-1512 • Description of metabolites in vitro.
50. 11418 American Society of Clinical Oncology - 37th Annual Meeting (Part X), San Francisco, CA, USA. Morse M IDDB MEETING REPORT2QO May 12-15